Brachytherapy: A critical component of primary radiation therapy for cervical cancer: From the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS).


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
03 2019
Historique:
received: 28 08 2018
revised: 11 10 2018
accepted: 15 10 2018
pubmed: 23 1 2019
medline: 18 4 2019
entrez: 23 1 2019
Statut: ppublish

Résumé

Brachytherapy is well-established as an integral component in the standard of care for treatment of patients receiving primary radiotherapy for cervical cancer. A decline in brachytherapy has been associated with negative impacts on survival in the era of modern EBRT techniques. Conformal external beam therapies such intensity modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT) should not be used as alternatives to brachytherapy in patients undergoing primary curative-intent radiation therapy for cervical cancer. Computed tomography or magnetic resonance image-guided adaptive brachytherapy is evolving as the preferred brachytherapy method. With careful care coordination EBRT and brachytherapy can be successfully delivered at different treatment centers without compromising treatment time and outcome in areas where access to brachytherapy maybe limited.

Identifiants

pubmed: 30665615
pii: S0090-8258(18)31297-6
doi: 10.1016/j.ygyno.2018.10.016
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

540-547

Informations de copyright

Copyright © 2018 Elsevier Inc., American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Christine H Holschneider (CH)

Gynecologic Oncology, Olive View-UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America. Electronic address: cholschneider@dhs.lacounty.gov.

Daniel G Petereit (DG)

Radiation Oncology, , Regional Health - John T. Vucurevich Cancer Care Institute, Rapid City, SD, United States of America.

Christina Chu (C)

Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States of America.

I-Chow Hsu (IC)

Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States of America.

Yevgeniya J Ioffe (YJ)

Gynecologic Oncology, Loma Linda University, Loma Linda, CA, United States of America.

Ann H Klopp (AH)

Radiation Oncology, MD Anderson Cancer Center, Houston, TX, United States of America.

Bhavana Pothuri (B)

Gynecologic Oncology, NYU Langone Laura and Isaac Perlmutter Cancer Center, New York, NY, United States of America.

Lee-May Chen (LM)

Gynecologic Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States of America.

Catheryn Yashar (C)

Radiation Oncology, UC San Diego School of Medicine, San Diego, CA, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH